使用多种核医学影像生物标志物评估新型选择性雌激素受体降解剂SAR439859靶点结合与早期疗效的转化策略
在小鼠MCF7-Y537S突变ERα阳性乳腺癌模型中,使用FES-PET、FDG-PET和FLT-PET评估SERD化合物SAR439859的靶点结合与早期疗效。结果显示SAR439859治疗4天后FES肿瘤摄取呈剂量依赖性下降,且与ERα免疫组化评分相关;FDG摄取无显著变化;FLT摄取在palbociclib联合SAR439859时显著降低。
要点
- SAR439859治疗4天后FES肿瘤摄取较基线呈剂量依赖性下降,与ERα表达免疫组化评分相关。
- SAR439859治疗3天后FDG摄取无显著变化。
- palbociclib联合SAR439859时FLT肿瘤累积显著降低,与palbociclib单药组无显著差异。
核心结论
- 临床前研究中,FES肿瘤摄取呈剂量依赖性抑制,证实SAR439859与ERα的靶点结合。
- FES-PET似乎是用于无创测量SAR439859对肿瘤雌激素受体占有率影响的相关影像生物标志物。
- 本研究进一步验证了FLT-PET可直接可视化palbociclib CDK 4/6抑制剂单药及联合SAR439859的抗增殖肿瘤效应。
研究设计与样本
- 在皮下MCF7-Y537S突变ERα阳性乳腺癌模型小鼠中,研究FES-PET、FDG-PET和FLT-PET作为早期药效学、肿瘤代谢和肿瘤增殖影像生物标志物。
- 通过免疫组化评估ER表达和增殖指数Ki-67。
- 测试palbociclib CDK 4/6抑制剂联合SAR439859的潜在协同抗肿瘤活性。
主要发现
- 重复口服SAR439859 4天后,FES肿瘤摄取(SUVmean)较基线分别下降:25 mg/kg qd组35%、12.5 mg/kg bid组57%、5 mg/kg bid组55%。
- SAR439859不同剂量治疗后FES肿瘤摄取与ERα表达免疫组化评分相关。
- SAR439859治疗3天后FDG摄取无显著差异。
- palbociclib联合SAR439859时FLT肿瘤累积显著降低(-64%),但与palbociclib单药组(-46%)无显著差异。
- Ki-67免疫组化数据证实了两组治疗对增殖的影响。
关键数值与推荐
- FES肿瘤摄取(SUVmean)较基线下降:25 mg/kg qd组35%、12.5 mg/kg bid组57%、5 mg/kg bid组55%。
- palbociclib联合SAR439859组FLT肿瘤累积降低64%,palbociclib单药组降低46%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we interrogated sufficient estrogen receptor occupancy and degradation for the selective estrogen receptor degrader (SERD) compound SAR439859 using molecular imaging and histological techniques. MATERIAL AND METHODS: [18F]FluoroEstradiol positron emission tomography (FES-PET), [18F]FluoroDeoxyGlucose (FDG) PET, and [18F]FluoroThymidine (FLT) PET were investigated as early pharmacodynamic, tumor metabolism, and tumor proliferation imaging biomarkers, respectively, in mice bearing subcutaneous MCF7-Y537S mutant ERα+ breast cancer model treated with the SERD agent SAR439859. ER expression and proliferation index Ki-67 were assessed by immunohistochemistry (IHC). The combination of palbociclib CDK 4/6 inhibitor with SAR439859 was tested for its potential synergistic effect on anti-tumor activity. RESULTS: After repeated SAR439859 oral administration over 4 days, FES tumoral uptake (SUVmean) decreases compared to baseline by 35, 57, and 55% for the 25 mg/kg qd, 12.5 mg/kg bid and 5 mg/kg bid treatment groups, respectively. FES tumor uptake following SAR439859 treatment at different doses correlates with immunohistochemical scoring for ERα expression. No significant difference in FDG uptake is observed after SAR439859 treatments over 3 days. FLT accumulation in tumor is significantly decreased when palbociclib is combined to SAR439859 (- 64%) but not different from the group dosed with palbociclib alone (- 46%). The impact on proliferation is corroborated by Ki-67 IHC data for both groups of treatment. CONCLUSIONS: In our preclinical studies, dose-dependent inhibition of FES tumoral uptake confirmed target engagement of SAR439859 to ERα. FES-PET thus appears as a relevant imaging biomarker for measuring non-invasively the impact of SAR439859 on tumor estrogen receptor occupancy. This study further validates the use of FLT-PET to directly visualize the anti-proliferative tumor effect of the palbociclib CDK 4/6 inhibitor alone and in combination with SAR439859.
引用
- Besret L, d'Heilly S, Aubert C, et al. Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader. EJNMMI Res. 2020. PMID: 32601772. doi:10.1186/s13550-020-00646-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。